Kronos Bio Inc. (KRON)
NASDAQ (CM) NASDAQ (CM) Primary Summary
KRON Chart
Kronos Bio downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler analyst Edward Tenthoff downgraded Kronos Bio to Neutral from Overweight with a price target of $1, down from $6.
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.54 per share a year ago.
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
The heavy selling pressure might have exhausted for Kronos Bio (KRON) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Kronos Bio Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 950 | $13 | $13 | - | - |
Kronos Bio Inc. (KRON) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Kronos Bio Inc. Profile
| - Industry | - Sector | Deborah A. Knobelman CEO | NASDAQ (CM) Exchange | 50107A104 CUSIP |
| US Country | 8 Employees | - Last Dividend | 3 Nov 2003 Last Split | 9 Oct 2020 IPO Date |
Overview
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company that has set its sights on the ambitious goal of discovering and developing innovative therapeutics aimed at treating a wide range of cancers as well as other serious diseases. Founded in 2017, the company has swiftly positioned itself within the dynamic landscape of the healthcare sector in the United States. Based in San Mateo, California, Kronos Bio leverages cutting-edge research and development strategies to tackle some of the most challenging diseases facing patients today.
Products and Services
The company's pipeline of lead product candidates includes:
- KB-0742:
An oral cyclin dependent kinase 9 inhibitor that has reached Phase 2 clinical trials. This promising candidate is specifically designed for the treatment of MYC-amplified solid tumors, showcasing Kronos Bio's focused approach in targeting cancer's molecular drivers.
- KB-9558:
A transformative approach towards treating multiple myeloma, focusing on a core oncogenic transcription factor integral to the disease. This indicates Kronos Bio's commitment to addressing hard-to-treat cancers by targeting their fundamental biological mechanisms.
